Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Rare Disease Voucher Program Faces Expiration

Executive Summary

Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.

You may also be interested in...



Rare Pediatric Priority Review Voucher Program Seems Headed For Short-Term Renewal

Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.

Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee

Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel